How to Decide on the Optimal Duration of Anticoagulant Therapy in Carriers of the Factor V Leiden Mutation

Saskia Middeldorp; Harry R. Büller

doi:10.1055/s-0037-1614107

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2000; 84(05): 740-741
DOI: 10.1055/s-0037-1614107

Commentary

Schattauer GmbH

How to Decide on the Optimal Duration of Anticoagulant Therapy in Carriers of the Factor V Leiden Mutation

Saskia Middeldorp

¹From the Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

,

Harry R. Büller

¹From the Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

References
1 Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
2 Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K-A, Hjorth M, Linder O, Boberg J. the Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Eng J Med 1995; 332: 1661-5.
3 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells PS, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Eng J Med 1999; 340: 901-7.
4 Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Ascani A, Bazzan M, Alatri A, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, Iorio A. for the WODIT Investigators. Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: the Warfarin Optimal Duration Italian Trial (WODIT). Thromb Haemost 1999; 82: 684-5.
5 Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Int Med 1996; 125: 1-7.
6 Van den Belt AGM, Hutten BA, Prins MH, Bossuyt PMM. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S. A decision analysis. Thromb Haemost 2000; 84: 758-63.
7 Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden: costeffectiveness analysis. Thromb Haemost 2000; 84: 752-7.
8 Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ 1998; 316: 95-9.